Status:
UNKNOWN
HIV A6 Genome In ART Unsuccessful Patients On DOR
Lead Sponsor:
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Collaborating Sponsors:
MSD Pharmaceuticals LLC
Conditions:
Virus-HIV
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to evaluate the efficacy of Doravirine (DOR) in the second-line therapy for patients infected with HIV-1 sub-subtype A6 and its derivatives and having the mutations to previous...
Detailed Description
During the study 60-80 HIV-infected patients in 2-4 investigation sites (AIDS Centers) across Russia with proven virological failure on first-line antiretroviral therapy (ART) including efavirenz (EFV...
Eligibility Criteria
Inclusion
- HIV-infection confirmed
- \> 18 years
- Informed consent signed
Exclusion
- Pregnant women
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05322083
Start Date
May 1 2022
End Date
January 1 2024
Last Update
April 11 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.